Practitioner Updates

In certain situations, inducing emesis in dogs may be required. A flow chart has been developed by veterinarians from Auburn University indicating when it is and is not appropriate to induce emesis. The authors do…
Read More >

Ten years ago, Dr. Devon Hague joined our hospital’s clinical faculty to rebuild a neurology service that had been without a boarded neurologist for 10 years. Aided by Denise Weber, a veterinary technician with extensive…
Read More >

Kamerer is the clinical trials coordinator for the oncology service. Tell us about your background. I am a true townie, born and raised right here in Champaign-Urbana. I went to veterinary technician school at Parkland…
Read More >

Fig. 1. A dog with moderate cardiomegaly with a VHS of 11.5. There is evidence of left atrial enlargement. The pulmonary vessels and parenchyma are unremarkable with no evidence of cardiogenic pulmonary edema. Thoracic radiographs…
Read More >

Proper administration and dosing of insulin is imperative to achieve maximum efficacy while avoiding hypoglycemia. Therefore, accuracy and precision of dose administration is crucial. There are two techniques for insulin administration in pets: by vial…
Read More >

Dr. Lowery is part of the hospital’s food animal reproduction medicine service (FARMS). Tell us about your background. I originally grew up on a family-owned dairy farm in Mazon, Ill., about one hour south of…
Read More >

Two new clinical trials involve bringing new therapies developed by external companies to dogs with naturally occurring disease to evaluate the drug’s effectiveness. Immunotherapy in Canine Oral Malignant Melanoma A trial led by Dr. Tim…
Read More >

Dezzi, shown wearing a scarf that says, “I’m a fighter,” presented with oral malignant melanoma and received cytokine therapy. Tim Fan, DVM, PhD, DACVIM (Oncology; Small Animal Internal Medicine)  To reduce cancer-related deaths in pets,…
Read More >

It is impossible to chemically synthesize an exact and identical copy of a biological. In July 2021, the FDA approved Semglee (insulin glargine-yfgn), the first interchangeable biosimilar insulin product for Lantus (insulin glargine).1 Insulin glargine…
Read More >